Health Canada Approves Mounjaro to Lower the Risk of Heart Attack, Stroke, and Cardiovascular Death in Type 2 Diabetes
Health Canada added a new use for Lilly's Mounjaro (tirzepatide): lowering the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes and established cardiovascular disease, Lilly Canada announced November 18. The approval rests on SURPASS-CVOT, which compared tirzepatide with dulaglutide (Trulicity) in more than 13,000 people across 30 countries for over four and a half years. Tirzepatide met the trial's non-inferiority goal with an 8% lower rate of these events (hazard ratio 0.92, 95.3% CI 0.83 to 1.01), a range that does not rule out no difference. The release says nothing about price or public coverage.